keyword
MENU ▼
Read by QxMD icon Read
search

high risk prostate cancer

keyword
https://www.readbyqxmd.com/read/29353450/cancer-treatment-and-bone-health
#1
REVIEW
Catherine Handforth, Stella D'Oronzo, Robert Coleman, Janet Brown
Considerable advances in oncology over recent decades have led to improved survival, while raising concerns about long-term consequences of anticancer treatments. In patients with breast or prostate malignancies, bone health is a major issue due to the high risk of bone metastases and the frequent prolonged use of hormone therapies that alter physiological bone turnover, leading to increased fracture risk. Thus, the onset of cancer treatment-induced bone loss (CTIBL) should be considered by clinicians and recent guidelines should be routinely applied to these patients...
January 20, 2018: Calcified Tissue International
https://www.readbyqxmd.com/read/29344682/68ga-prostate-specific-membrane-antigen-psma-positron-emission-tomography-pet-for-primary-staging-of-high-risk-prostate-cancer-a-systematic-review
#2
Julia Corfield, Marlon Perera, Damien Bolton, Nathan Lawrentschuk
PURPOSE: To systematically review currently available data on 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) used for the primary staging of high-risk prostate cancer. METHODS: We performed critical reviews of EMBASE, Web of Science (including MEDLINE) and Cochrane databases in October 2016 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. We included studies that utilized 68Ga-PSMA PET for primary staging of prostate cancer...
January 17, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29339663/evaluation-of-magnetic-resonance-imaging-ultrasound-fusion-biopsy-in-patients-with-low-risk-prostate-cancer-under-active-surveillance-undergoing-surveillance-biopsy
#3
Angelika Borkowetz, Theresa Renner, Ivan Platzek, Marieta Toma, Roman Herout, Martin Baunacke, Christer Groeben, Johannes Huber, Michael Laniado, Gustavo B Baretton, Michael Froehner, Stefan Zastrow, Manfred P Wirth
INTRODUCTION: Targeted biopsy of tumour-suspicious lesions detected in multiparametric magnetic resonance imaging (mpMRI) plays an increasing role in the active surveillance (AS) of patients with low-risk prostate cancer (PCa). The aim of this study was to compare MRI/ultrasound-fusion biopsy (fusPbx) with systematic biopsy (sysPbx) in patients undergoing biopsy for AS. METHODS: Patients undergoing mpMRI and transperineal fusPbx combined with transrectal sysPbx (comPbx) as surveillance biopsy were investigated...
January 16, 2018: Urologia Internationalis
https://www.readbyqxmd.com/read/29339090/patched-1-expression-correlates-with-biochemical-relapse-in-high-risk-prostate-cancer-patients
#4
Annelies Gonnissen, Sofie Isebaert, Christiaan Perneel, Chad M McKee, Filip Van Utterbeeck, Evelyne Lerut, Clare Verrill, Richard J Bryant, Steven Joniau, Ruth J Muschel, Karin Haustermans
There is an unmet clinical need for adequate biomarkers to aid risk stratification and management of prostate cancer (PCa) patients. Even within the high-risk PCa category not all patients will invariably have a poor prognosis, and improved stratification of this heterogeneous group is needed. In this context, components of the hedgehog (Hh) pathway may have promise as biomarkers, as the available evidence suggests increased Hh pathway activity may confer a poorer outcome in advanced and castrate-resistant PCa...
January 12, 2018: American Journal of Pathology
https://www.readbyqxmd.com/read/29339046/stereotactic-body-radiation-therapy-sbrt-for-high-risk-prostate-cancer-where-are-we-now
#5
REVIEW
Alejandro Gonzalez-Motta, Mack Roach
PURPOSE: Stereotactic body radiation therapy (SBRT) is increasingly being used for the management of localized prostate cancer. This trend combined with declining use of brachytherapy (BT) has pushed issues and questions regarding the use of SBRT to the forefront. A systematic literature review was conducted to review the current evidence of biochemical disease-free survival (bDFS) and toxicity of SBRT in high-risk (HR) prostate cancer. METHODS AND MATERIALS: A search was carried out on the PubMed and Embase databases...
December 2, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29339044/the-cardiovascular-toxicity-of-abiraterone-and-enzalutamide-in-prostate-cancer
#6
Roberto Iacovelli, Chiara Ciccarese, Emilio Bria, Mario Romano, Emanuela Fantinel, Davide Bimbatti, Alessandro Muraglia, Antonio Benito Porcaro, Salvatore Siracusano, Matteo Brunelli, Renzo Mazzarotto, Walter Artibani, Giampaolo Tortora
INTRODUCTION: The cardiovascular toxicity related to abiraterone and enzalutamide has been previously studied by our group. In this analysis, we aim to update our previous findings related to abiraterone and enzalutamide, including the new available evidence, both in castration-resistant and hormone-sensitive prostate cancer. PATIENTS AND METHODS: Prospective studies were identified by searching the MEDLINE/PubMed, Cochrane Library, and ASCO Meeting abstracts. Combined relative risks (RRs) and 95% confidence intervals (CIs) were calculated using fixed- or random-effects methods...
December 27, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29338305/safety-and-feasibility-of-prostate-stereotactic-ablative-radiotherapy-using-multi-modality-imaging-and-flattening-filter-free
#7
Aileen Duffton, Azmat Sadozye, Lynsey Devlin, Nicholas MacLeod, Carolynn Lamb, Suzanne Smith, Philip McLoone, Muthu Sankaralingam, John Foster, Stephanie Paterson, Stefanie Keatings, David Dodds
PURPOSE: To investigate feasibility and safety of SABR in the management of prostate cancer while employing MR/CT fusion for delineation, fiducial markers seeds for positioning and Varian Rapidarc with FFF delivery. METHODS: Forty-one patients were treated for low-intermediate risk prostate cancer with initial PSA (iPSA) of ≤20ng/ml, Gleason score 6-7. Patients had MR/CT fusion for delineation of prostate +/-seminal vesicles. CT/MR fusion images were used for delineation and planned using flattening filter free modality...
January 17, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29338073/impact-of-time-to-testosterone-rebound-and-comorbidity-on-the-risk-of-cause-specific-mortality-in-men-with-unfavorable-risk-prostate-cancer
#8
Susan G R McDuff, Ming-Hui Chen, Andrew A Renshaw, Marian J Loffredo, Philip W Kantoff, Anthony V D'Amico
BACKGROUND: Herein, the authors evaluated how the time to testosterone rebound (TTR) after radiotherapy (RT) and 6 months of androgen deprivation therapy (ADT) impacted the risk of prostate cancer-specific mortality (PCSM) and cardiovascular-specific mortality (CVM) among men with varying comorbidity extent. METHODS: Between 1995 and 2001, a total of 206 men who were randomized to receive RT either alone or with 6 months of ADT for unfavorable-risk PC and who had a comorbidity score assigned using the Adult Comorbidity Evaluation 27 metric comprised the study cohort...
January 16, 2018: Cancer
https://www.readbyqxmd.com/read/29336978/metastatic-burden-in-newly-diagnosed-hormone-naive-metastatic-prostate-cancer-comparing-definitions-of-chaarted-and-latitude-trial
#9
Sarah Buelens, Filip Poelaert, Bert Dhondt, Valérie Fonteyne, Pieter De Visschere, Piet Ost, Sofie Verbeke, Geert Villeirs, Kathia De Man, Sylvie Rottey, Karel Decaestecker, Nicolaas Lumen
OBJECTIVES: No uniformity exists in the definition of metastatic burden in metastatic hormone-naive prostate cancer (mHNPC) across clinical trials making their comparison challenging. We explored definition agreement and prognostic significance of bulky mHNPC according to the CHAARTED and LATITUDE trial. MATERIALS AND METHODS: Since 2014, 95 patients with newly diagnosed mHNPC were prospectively registered. For this study, they were categorized as having high-volume (HVD) vs...
January 11, 2018: Urologic Oncology
https://www.readbyqxmd.com/read/29336835/standard-whole-prostate-gland-radiotherapy-with-and-without-lesion-boost-in-prostate-cancer-toxicity-in-the-flame-randomized-controlled-trial
#10
Evelyn M Monninkhof, Juliette W L van Loon, Marco van Vulpen, Linda G W Kerkmeijer, Floris J Pos, Karin Haustermans, Laura van den Bergh, Sofie Isebaert, Gill M McColl, Robert Jan Smeenk, Juus Noteboom, Iris Walraven, Petra H M Peeters, Uulke A van der Heide
PURPOSE: To compare toxicity rates in patients with localized prostate cancer treated with standard fractionated external beam radiotherapy (EBRT) with or without an additional integrated boost to the macroscopically visible tumour. MATERIAL AND METHODS: FLAME is a phase 3 multicentre RCT (NCT01168479) of patients with pathologically confirmed localized intermediate or high-risk prostate cancer. The standard treatment arm (n = 287) received a dose to the entire prostate of 77 Gy in 35 fractions...
January 11, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29333577/prostate-cancer-patients-understanding-of-the-gleason-scoring-system-implications-for-shared-decision-making
#11
Erin K Tagai, Suzanne M Miller, Alexander Kutikov, Michael A Diefenbach, Ronak A Gor, Tahseen Al-Saleem, David Y T Chen, Sara Fleszar, Gem Roy
The Gleason scoring system is a key component of a prostate cancer diagnosis, since it indicates disease aggressiveness. It also serves as a risk communication tool that facilitates shared treatment decision-making. However, the system is highly complex and therefore difficult to communicate: factors which have been shown to undermine well-informed and high-quality shared treatment decision-making. To systematically explore prostate cancer patients' understanding of the Gleason scoring system (GSS), we assessed knowledge and perceived importance among men who had completed treatment (N = 50)...
January 15, 2018: Journal of Cancer Education: the Official Journal of the American Association for Cancer Education
https://www.readbyqxmd.com/read/29332451/psca-rs1045531-polymorphism-and-the-risk-of-prostate-cancer-in-a-chinese-population-undergoing-prostate-biopsy
#12
Xuefeng Zhang, Qin Hu, Ye Chen, Miao Li, Huming Yin, Chenchao Zhou, Gang Li, Jianquan Hou
BACKGROUND AND PURPOSE: This study explored the association between a single-nucleotide polymorphism of prostate stem cell antigen and prostate cancer in Chinese patients undergoing prostate biopsy. MATERIALS AND METHODS: DNA from 416 patients undergoing prostate biopsy was typed for the prostate stem cell antigen rs1045531 single-nucleotide polymorphism. The frequency of the rs1045531 polymorphism in patients with prostate cancer and in patients with benign prostatic hyperplasia was compared...
December 2017: Technology in Cancer Research & Treatment
https://www.readbyqxmd.com/read/29332260/prostate-cancer-rates-in-patients-with-initially-negative-elastography-targeted-biopsy-vs-systematic-biopsy
#13
Jeannette Kratzenberg, Georg Salomon, Pierre Tennstedt, Paolo Dell'Oglio, Derya Tilki, Axel Haferkamp, Markus Graefen, Katharina Boehm
PURPOSE: To assess whether real-time elastography-targeted biopsy (RTE-bx) is superior to the standard systematic transrectal ultrasound (TRUS)-guided biopsy in predicting subsequent prostate cancer (PCa) rates in patients with initially negative biopsy and to specifically reveal differences in the occurrence of high-grade (Gleason ≥ 4 + 3) PCa by comparing both biopsy methods. PATIENTS AND METHODS: Overall, 630 patients had an initially negative prostate biopsy between 2007 and 2015, either RTE targeted (n = 213) or systematically (n = 417)...
January 13, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29331622/value-of-serial-multiparametric-magnetic-resonance-imaging-and-magnetic-resonance-imaging-guided-biopsies-in-men-with-low-risk-prostate-cancer-on-active-surveillance-after-1-yr-follow-up
#14
Esther Hendrika Johanna Hamoen, Caroline M A Hoeks, Diederik M Somford, Inge M van Oort, Henk Vergunst, Jorg R Oddens, Geert A Smits, Leonard P Bokhorst, J Alfred Witjes, Maroeska M Rovers, Christina A Hulsbergen-van de Kaa, Jelle O Barentsz
BACKGROUND: Active surveillance (AS) aims to reduce overtreatment of low-risk prostate cancer (PC). Incorporating multiparametric magnetic resonance imaging (mp-MRI) and MR-guided biopsy (MRGB) in an AS protocol might contribute to more accurate identification of AS candidates. OBJECTIVE: To evaluate the value of 3T mp-MRI and MRGB in PC patients on AS at inclusion and after 12-mo follow-up. DESIGN, SETTING, AND PARTICIPANTS: Patients with cT1c-cT2 PC, prostate-specific antigen (PSA) ≤10ng/ml, PSA density <0...
January 10, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29331546/clinically-localized-prostate-cancer-aua-astro-suo-guideline-part-ii-recommended-approaches-and-details-of-specific-care-options
#15
Martin G Sanda, Jeffrey A Cadeddu, Erin Kirkby, Ronald C Chen, Tony Crispino, Joann Fontanarosa, Stephen J Freedland, Kirsten Greene, Laurence H Klotz, Danil V Makarov, Joel B Nelson, George Rodrigues, Howard M Sandler, Mary Ellen Taplin, Jonathan R Treadwell
PURPOSE: This guideline is structured to provide a clinical framework stratified by cancer severity to facilitate care decisions and guide the specifics of implementing the selected management options. The summary presented herein represents Part II of the two-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline discussing risk stratification and care options by cancer severity. Please refer to Part I for discussion of specific care options and outcome expectations and management...
January 10, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29331524/strategies-and-technical-challenges-for-imaging-oligometastatic-disease-recommendations-from-the-european-organisation-for-research-and-treatment-of-cancer-imaging-group
#16
REVIEW
Nandita M deSouza, Yan Liu, Arturo Chiti, Daniela Oprea-Lager, Géraldine Gebhart, Bernard E Van Beers, Ken Herrmann, Frederic E Lecouvet
Patients with oligometastatic disease (OMD) often have controllable symptoms, and cures are possible. Technical improvements in surgery and radiotherapy have introduced the option of metastasis-directed ablative therapies as an adjunct or alternative to standard-of-care systemic therapies. Several clinical trials and registries are investigating the benefit of these therapeutic approaches across several cancer sites. This requires that patients are correctly included and followed with appropriate imaging. This article discusses the evidence and offers recommendations for the implementation of standard-of-care (Response Evaluation Criteria in Solid Tumours measurements on computed tomography [CT], magnetic resonance imaging [MRI] and bone scintigraphy) and advanced imaging modalities (functional, metabolic and radionuclide targeted) for identifying and following up patients with OMD...
January 10, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29328959/impact-of-individual-and-neighborhood-factors-on-disparities-in-prostate-cancer-survival
#17
Mindy C DeRouen, Clayton W Schupp, Jocelyn Koo, Juan Yang, Andrew Hertz, Salma Shariff-Marco, Myles Cockburn, David O Nelson, Sue A Ingles, Esther M John, Scarlett L Gomez
BACKGROUND: We addressed the hypothesis that individual-level factors act jointly with social and built environment factors to influence overall survival for men with prostate cancer and contribute to racial/ethnic and socioeconomic (SES) survival disparities. METHODS: We analyzed multi-level data, combining (1) individual-level data from the California Collaborative Prostate Cancer Study, a population-based study of non-Hispanic White (NHW), Hispanic, and African American prostate cancer cases (N = 1800) diagnosed from 1997 to 2003, with (2) data on neighborhood SES (nSES) and social and built environment factors from the California Neighborhoods Data System, and (3) data on tumor characteristics, treatment and follow-up through 2009 from the California Cancer Registry...
January 9, 2018: Cancer Epidemiology
https://www.readbyqxmd.com/read/29326030/patient-reported-outcomes-following-abiraterone-acetate-plus-prednisone-added-to-androgen-deprivation-therapy-in-patients-with-newly-diagnosed-metastatic-castration-naive-prostate-cancer-latitude-an-international-randomised-phase-3-trial
#18
Kim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, Gaetano Facchini, Henrik Suttman, Nobuaki Matsubara, Zhangqun Ye, Bhumsuk Keam, Ronaldo Damião, Tracy Li, Kelly McQuarrie, Bin Jia, Peter De Porre, Jason Martin, Mary B Todd, Karim Fizazi
BACKGROUND: In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer. Understanding the effects of treatments on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) is important for treatment decisions; therefore we aimed to analyse the effects of ADT plus abiraterone acetate and prednisone versus ADT plus placebos on PROs and HRQOL in patients in the LATITUDE study...
January 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29325033/cancer-risk-in-older-people-living-with-human-immunodeficiency-virus-infection-in-the-united-states
#19
Parag Mahale, Eric A Engels, Anna E Coghill, Amy R Kahn, Meredith S Shiels
Background: Cancer risk is increased in people living with HIV (PLWH). Improved survival has led to an aging of PLWH. We evaluated the cancer risk in older PLWH (age ≥50 years). Methods: We included data from the HIV/AIDS Cancer Match Study (1996-2012) and evaluated risk of Kaposi sarcoma (KS), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, and cervical, anal, lung, liver, oral cavity/pharyngeal, breast, prostate, and colon cancers in older PLWH compared to the general population by calculating the standardized incidence ratios (SIRs) and excess absolute risks (EARs)...
January 8, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29323548/18f-fluorocholine-pet-whole-body-mri-in-the-staging-of-high-risk-prostate-cancer
#20
Ur Metser, Alejandro Berlin, Jaydeep Halankar, Grainne Murphy, Kartik S Jhaveri, Sangeet Ghai, Noam Tau
OBJECTIVE: The purpose of this study was to determine whether integrated 18F-fluorocholine (FCH) PET whole-body MRI (PET/WBMRI) depicts lymph node and distant metastases in patients with high-risk prostate cancer more frequently than does conventional staging. SUBJECTS AND METHODS: A prospective study included 58 patients with untreated high-risk prostate cancer. After conventional staging (CT and bone scintigraphy), patients underwent FCH PET/WBMRI (n = 10) or FCH PET/CT and WBMRI (n = 48)...
January 11, 2018: AJR. American Journal of Roentgenology
keyword
keyword
69231
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"